Shots:

• The US FDA has approved the inclusion of OS data based on P-III PACIFIC study results in an update to the Imfinzi (durvalumab) US prescribing information for patients with unresectable- Stage III NSCLC prior not treated with platinum-based CT and radiation therapy (CRT)
• The P-III study results demonstrated OS benefit by reducing the risk of death by 32% following 3yrs. post-hoc OS analysis showing 31% reduction in risk of death and 57% are still alive patients vs 44% with PBO
• Imfinzi is a mAb targeting PD-L1- blocking its interaction with PD-1 and CD80 to counter the tumor's immune-evading tactics and is an approved therapy in 45+ countries including the US- EU and Japan

Click here to read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca